PTC124は,無意味な突然変異によって引き起こされる遺伝疾患をターゲットにしています
Ellen M Welch1, Elisabeth R Barton, Jin Zhuo
1PTC Therapeutics, 100 Corporate Court, South Plainfield, New Jersey 07080, USA.
Nature
|April 24, 2007
まとめ
新しい薬であるPTC124は,早期停止コドンのリボソームの読み込みを選択的に誘導し,潜在的に遺伝疾患を治療します. この薬は,タンパク質の生産を促進し,良好な耐受性を持つ臨床前モデルの筋肉機能を救う.
科学分野:
- 遺伝学 遺伝学とは
- 薬理学 薬理学とは
- 分子生物学は分子生物学である.
背景:
- 無意味な突然変異は,早すぎる翻訳終結を引き起こし,遺伝疾患の5〜70%につながります.
- 低濃度であっても,タンパク質合成の回復は,システィック線維症で見られるように,疾患の重症度を大幅に軽減することができます.
研究 の 目的:
- 早期終結コドンを選択的に抑制する薬物を特定するために.
- 遺伝疾患の治療のための特定された薬物,PTC124の有効性と安全性を評価する.
主な方法:
- 早期終結コドンの選択的なリボソームの読み込みのために,特定され,最適化されたPTC124.
- ナンセンスアレルを持つヒトおよびマウスの細胞におけるディストロフィン生成を促進するPTC124の能力を評価した.
- PTC124.4で治療されたmdxマウスの線状筋機能回復を評価した.
主要な成果:
- PTC124 選択的に誘発されたリボソームの読み込み 早期終結のコドン.
- 筋肉細胞ではディストロフィン生成が促進され,MDXマウスでは筋線状の筋肉機能が回復しました.
- PTC124は,効果的な用量で動物モデルで良好な耐受性を示した.
結論:
- PTC124は,無意味な変異によって引き起こされる幅広い遺伝疾患の治療の可能性を示しています.
- 薬剤の選択性,有効性,好ましい薬理学プロファイルは,その広範な臨床的可能性を支持しています.
さらに関連する動画
関連する概念動画
Mutations
Overview
Translation
Lesson: Translation
Translation is the process of synthesizing proteins from the genetic information carried by messenger RNA (mRNA). Following transcription, it constitutes the final step in the expression of genes. This process is carried out by ribosomes, complexes of protein and specialized RNA molecules. Ribosomes, transfer RNA (tRNA), and other proteins produce a chain of amino acids—the polypeptide—as the end product of translation.
Translation Produces the Building Blocks of Life
Translation is the process of synthesizing proteins from the genetic information carried by messenger RNA (mRNA). Following transcription, it constitutes the final step in the expression of genes. This process is carried out by ribosomes, complexes of protein and specialized RNA molecules. Ribosomes, transfer RNA (tRNA), and other proteins produce a chain of amino acids—the polypeptide—as the end product of translation.
Translation Produces the Building Blocks of Life
Nonsense-mediated mRNA Decay
The Upf proteins that carry out nonsense-mediated decay (NMD) are found in all eukaryotic organisms, including humans. Each protein has an individual role, but they need to work in collaboration. Upf1 is an ATP-dependent RNA helicase that unwinds the RNA helix. Because Upf1 can unwind any RNA, Upf2 and Upf3 are required to help Upf1 discriminate between nonsense and normal mRNAs.
Usually, Upf3 binds to an Exon Junction Complex (EJC) at mRNA splice sites. If a ribosome fully translates the mRNA,...
Usually, Upf3 binds to an Exon Junction Complex (EJC) at mRNA splice sites. If a ribosome fully translates the mRNA,...
Alternative RNA Splicing
Alternative RNA splicing is the regulated splicing of exons and introns to produce different mature mRNAs from a single pre-mRNA. Unlike in constitutive splicing where a single gene produces a single type of mRNA, alternative splicing allows an organism to produce multiple proteins from a single gene and plays an important role in protein diversity.
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...
Nonsense-mediated mRNA Decay
The Upf proteins that carry out nonsense-mediated decay (NMD) are found in all eukaryotic organisms, including humans. Each protein has an individual role, but they need to work in collaboration. Upf1 is an ATP-dependent RNA helicase that unwinds the RNA helix. Because Upf1 can unwind any RNA, Upf2 and Upf3 are required to help Upf1 discriminate between nonsense and normal mRNAs.
Usually, Upf3 binds to an Exon Junction Complex (EJC) at mRNA splice sites. If a ribosome fully translates the mRNA,...
Usually, Upf3 binds to an Exon Junction Complex (EJC) at mRNA splice sites. If a ribosome fully translates the mRNA,...
Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...


